No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ATXS240517P10000
- 0.61
- -0.12-16.44%
15min DelayClose May 15 15:59 ET
0.74High0.58Low
0.65Open0.73Pre Close4 Volume93 Open Interest10.00Strike Price258.00Turnover445.63%IV-10.46%PremiumMay 17, 2024Expiry Date0.73Intrinsic Value100Multiplier2DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type-0.5202Delta0.1260Gamma5.45Leverage Ratio-0.3377Theta-0.0004Rho-2.84Eff Leverage0.0028Vega
Intraday
- 5D
- 1D
News
Astria Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.
Astria Therapeutics Price Target Maintained With a $16.00/Share by HC Wainwright & Co.
Express News | Wedbush Reiterates Outperform on Astria Therapeutics, Maintains $22 Price Target
Astria TherapeuticS GAAP EPS of -$0.38 Misses by $0.02
Express News | Astria Therapeutics Q1 2024 GAAP EPS $(0.38), Inline
Astria Therapeutics Appointed Sunil Agarwal to Its Bd >ATXS
Astria Therapeutics Appointed Sunil Agarwal to Its Bd >ATXS
Astria Therapeutics 1Q Loss/Shr 38c >ATXS
Astria Therapeutics 1Q Loss/Shr 38c >ATXS
Comments
$Astria Therapeutics Inc(ATXS.US$ Astria Therapeutics Enters Worldwide Exclusive License Agreement With Ichnos Sciences For An OX40 Portfolio; To Pay Ichnos One-time Upfront License Fee Of $15M, Up To $305M In Milestones
Moomoo 24/7· 17 mins ago![]()
Moomoo 24/7· 17 mins ago
1
Read more
TrytosaveabitOP : Going on my watch list